Skip to main content

Iconix Signs Chemogenomics Collaboration with Icos

NEW YORK, June 24 (GenomeWeb News) - Iconix Pharmaceuticals will provide its chemogenomic profiling technology to Icos, the Mountain View, Calif.-based company said today.

 

Under the agreement, Icos will use Iconix's chemogenomics platform to study preclinical drug responses and to discover biomarkers to predict drug efficacy and side effects.

 

Iconix will use its Drug Signature collection of predictive biomarkers, derived from its DrugMatrix chemogenomics reference database.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.